1. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
- Author
-
Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, and Goulmy E
- Subjects
- Acetylation drug effects, Antigens, Neoplasm genetics, Antigens, Neoplasm immunology, Azacitidine pharmacology, Azacitidine therapeutic use, Cell Line, Tumor drug effects, Cell Line, Tumor metabolism, CpG Islands, DNA (Cytosine-5-)-Methyltransferase 1, DNA (Cytosine-5-)-Methyltransferases antagonists & inhibitors, Decitabine, Histones metabolism, Humans, Hydroxamic Acids pharmacology, Minor Histocompatibility Antigens genetics, Minor Histocompatibility Antigens immunology, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins metabolism, Neoplasms immunology, Neoplasms pathology, Oligopeptides genetics, Oligopeptides immunology, Promoter Regions, Genetic drug effects, Promoter Regions, Genetic genetics, Protein Processing, Post-Translational drug effects, RNA, Messenger biosynthesis, RNA, Neoplasm biosynthesis, T-Lymphocytes, Cytotoxic immunology, Transcription, Genetic, Antigens, Neoplasm biosynthesis, Azacitidine analogs & derivatives, DNA Methylation drug effects, DNA, Neoplasm drug effects, Gene Expression Regulation, Neoplastic drug effects, Gene Silencing drug effects, Immunotherapy methods, Minor Histocompatibility Antigens biosynthesis, Neoplasms genetics, Oligopeptides biosynthesis
- Abstract
Clinical responses of solid tumors after allogeneic human leukocyte antigen-matched stem cell transplantation (SCT) often coincide with severe graft-versus-host disease (GVHD). Targeting minor histocompatibility antigens (mHags) with hematopoiesis- and cancer-restricted expression, for example, HA-1, may allow boosting the antitumor effect of allogeneic SCT without risking severe GVHD. The mHag HA-1 is aberrantly expressed in cancers of most entities. However, an estimated 30% to 40% of solid tumors do not express HA-1 (ie, are HA-1(neg)) and cannot be targeted by HA-1-specific immunotherapy. Here, we investigated the transcriptional regulation of HA-1 gene expression in cancer. We found that DNA hypermethylation in the HA-1 promoter region is closely associated with the absence of HA-1 gene expression in solid tumor cell lines. Moreover, we detected HA-1 promoter hypermethylation in primary cancers. The hypomethylating agent 5-aza-2'-deoxycytidine induced HA-1 expression only in HA-1(neg) tumor cells and sensitized them for recognition by HA-1-specific cytotoxic T lymphocytes. Contrarily, the histone deacetylation inhibitor trichostatin A induced HA-1 expression both in some HA-1(neg) tumor cell lines and in normal nonhematopoietic cells. Our data suggest that promoter hypermethylation contributes to the HA-1 gene regulation in tumors. Hypomethylating drugs might extend the safe applicability of HA-1 as an immunotherapeutic target on solid tumors after allogeneic SCT.
- Published
- 2009
- Full Text
- View/download PDF